Ellen Callahan

Ellen Callahan is a seasoned professional in pharmacovigilance with extensive experience across multiple renowned pharmaceutical companies. Currently serving as a Drug Safety Associate at BioPoint Inc. since August 2022, Ellen is responsible for processing clinical trial serious unexpected adverse reactions (SUSARs), serious adverse events (SAEs), and adverse events of special interest (AESIs). Prior to this role, Ellen worked at Bristol Myers Squibb as a Senior Pharmacovigilance Scientist, where responsibilities included processing SUSAR Individual Case Safety Reports (ICSRs) for the Oncology portfolio and contributing to various regulatory safety documents. Ellen's background encompasses notable positions at Merck, Otsuka Pharmaceutical, and sanofi-aventis, including experiences in clinical risk management and the authorship of global safety documents. Educational credentials include a Master of Science in Pharmaceutical Quality Assurance & Regulatory Affairs from Temple University and a Bachelor of Science in Nursing from East Stroudsburg University of Pennsylvania.